Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p′DDD) levels on the treatment of patients with adrenocortical carcinoma

Cancer

Volumn 92, Issue 6, 2001, Pages 1385-1392

  Baudin, E ^a   Pellegriti, G ^a   Bonnay, M ^a   Penfornis, A ^b   Laplanche, A ^a   Vassal, G ^a   Schlumberger, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

1,1 dichlorodiphenildichloroethane; Adrenocortical carcinoma; Plasma levels

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; GYNECOMASTIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS;

ADRENAL CORTEX NEOPLASMS; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENVIRONMENTAL MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTANE; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0035883416     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2     Document Type: Article

References (27)

1. Adrenal cortical carcinoma: A study of 77 cases
2. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy
3. An eleven-year experience with adrenocortical carcinoma
4. Survival rates and prognostic factors in adrenocortical carcinoma
5. Adrenocortical tumors
6. Adrenocortical carcinoma
7. Adrenocortical carcinoma: Experience in 45 patients
8. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature
9. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study
10. Cytotoxic therapy with etoposide and cisplatin in advanced adrenal cortical carcinoma
11. Mitotane failure in adrenocortical cancer: Where next?
12. Chemotherapy of adrenocortical cancer with o, p′DDD
13. Clinical and pathophysiologic aspects of adrenocortical carcinoma
14. Adrenal cortical carcinoma: Results of treatment with o, p′DDD in 138 patients
15. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed in adrenocortical carcinomas
16. Treatment of adrenal carcinomas
17. Adrenal cortical carcinoma
18. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer
19. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients
20. Adrenocortical carcinoma - A clinical study and treatment results of 52 patients
21. Is there a role for low doses of mitotane (o, p′DDD) as adjuvant therapy in adrenocortical carcinoma?
22. Is there a role for low doses of mitotane (o, p′DDD) as adjuvant therapy in adrenocortical carcinoma [authors' response]?
23. The treatment of adrenocortical carcinoma with o, p′DDD: Prognostic implications of serum level monitoring
24. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer
25. Plasma levels of o, p′DDD following administration in various vehicles after a single dose and during long-term treatment
26. o, p′DDD (mitotane) treatment for Cushing's syndrome: Adrenal drug concentration and inhibition in vitro of steroid synthesis
27. Biological studies on an adrenocorticolytic agent and the isolation of the active components